Psykey, Inc. (CEOS) Research

Psykey, Inc. is dedicated to the exploration, formulation, and market introduction of specialized ingredients and compounds, including entheogenic, adaptogenic, and nootropic substances. These are incorporated into its functional product lines, which aim to enhance and optimize overall well-being. Furthermore, the company develops cutting-edge technologies focused on the makeup, bioavailability, and targeted administration of entheogen-derived therapeutics within the burgeoning psychedelic industry. Among its consumer offerings are functional mushroom coffees and teas, a variety of oral supplements, and convenient single-serve beverage mixes. The entity, which was established in Toronto, Canada, in 2002, previously operated as CeCors, Inc. before officially adopting the name Psykey, Inc. in August 2021.

Market snapshot

Symbol
CEOS
Price
$0.01
Day change
-2.62%
Market cap
$74.8K
P/E ratio
0.57x
52-week range
0.0006-0.0125
Sector
Healthcare
Industry
Medical - Instruments & Supplies

Peer companies

  • Abattis Bioceuticals Corp. (ATTBF)
  • Health Advance Inc. (HADV)
  • Health Discovery Corporation (HDVY)
  • Instadose Pharma Corp. (INSD)
  • Isodiol International Inc. (ISOLF)
  • Medivolve Inc. (MEDVF)
  • Nanobac Pharmaceuticals, Incorporated (NNBP)
  • OWC Pharmaceutical Research Corp. (OWCP)

Open Psykey, Inc. (CEOS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.